| 5594- | BEV, | immuno, | Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC |
| - | Human, | NSCLC, | NA |
| 5595- | BEV, | Chemo, | Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer |
| - | Human, | CRC, | NA |
| 5596- | BEV, | Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study |
| - | Study, | GBM, | NA |
| 5722- | BF, | Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 |
| 5729- | BF, | Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling |
| - | in-vitro, | Lung, | NA |
| 5723- | BF, | Unique Oxidative Metabolism of Bufalin Generates Two Reactive Metabolites That Strongly Inactivate Human Cytochrome P450 3A |
| - | Study, | NA, | NA |
| 5724- | BF, | A Novel Bufalin Derivative Exhibited Stronger Apoptosis-Inducing Effect than Bufalin in A549 Lung Cancer Cells and Lower Acute Toxicity in Mice |
| - | vitro+vivo, | Lung, | A549 |
| 5725- | BF, | TMZ, | Bufalin Induces Apoptosis and Improves the Sensitivity of Human Glioma Stem-Like Cells to Temozolamide |
| - | in-vitro, | GBM, | NA |
| 5726- | BF, | Bufalin exerts antitumor effects in neuroblastoma via the induction of reactive oxygen species-mediated apoptosis by targeting the electron transport chain |
| - | Review, | neuroblastoma, | SK-N-BE |
| 5727- | BF, | Bufalin Inhibits Proliferation and Induces Apoptosis in Osteosarcoma Cells by Downregulating MicroRNA-221 |
| - | in-vitro, | OS, | U2OS |
| 5728- | BF, | Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action |
| - | in-vitro, | Lung, | A549 |
| 5721- | BF, | Bufalin Suppresses Triple-Negative Breast Cancer Stem Cell Growth by Inhibiting the Wnt/β-Catenin Signaling Pathway |
| - | in-vitro, | BC, | NA |
| 5720- | BF, | Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway |
| - | in-vitro, | NSCLC, | NA |
| 5730- | BF, | Bufalin Is a Potent Small-Molecule Inhibitor of the Steroid Receptor Coactivators SRC-3 and SRC-1 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 |
| 5719- | BF, | Bufalin inhibits the proliferation of lung cancer cells by suppressing Hippo-YAP pathway |
| - | in-vitro, | Lung, | NA |
| 5718- | BF, | Bufalin inhibits CYP3A4 activity in vitro and in vivo |
| - | in-vivo, | Nor, | NA |
| - | Trial, | Var, | NA |
| 5716- | BF, | Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, or Pancreatic Cancer |
| - | Trial, | NSCLC, | NA | - | Trial, | PC, | NA | - | Trial, | HCC, | NA |
| 5715- | BF, | Bufalin for an innovative therapeutic approach against cancer |
| - | Review, | Var, | NA |
| 5597- | Bical, | Bicalutamide: clinical pharmacokinetics and metabolism |
| - | Review, | Pca, | NA |
| 2502- | Bical, | Complete Response of Metastatic Androgen Receptor–Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature |
| - | Case Report, | BC, | NA |
| 1250- | Bif, | Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12 |
| - | in-vitro, | SCC, | NA |
| 5621- | Bif, | immuno, | Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy |
| 5622- | Bif, | Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice |
| - | in-vivo, | Var, | NA |
| 5623- | Bif, | Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients |
| - | Study, | NSCLC, | NA |
| 5625- | Bif, | immuno, | The gut microbiome and cancer response to immune checkpoint inhibitors |
| - | Review, | Var, | NA |
| 5626- | Bif, | Bifidobacterium in anticancer immunochemotherapy: friend or foe? |
| - | Review, | Var, | NA |
| 5627- | Bif, | Efficacy and Safety of Probiotics as Adjunctive Therapy in Cancer Treatment: A Comprehensive Systematic Review and Meta-Analysis |
| - | Review, | Var, | NA |
| 5628- | Bif, | immuno, | Bifidobacterium modulation of tumor immunotherapy and its mechanism |
| - | Review, | Var, | NA |
| 5629- | Bif, | ProBio, | Gut microbiota shapes cancer immunotherapy responses |
| - | Review, | Var, | NA |
| 5688- | BJ, | Brucea Javanica Oil Emulsion Injection inhibits proliferation of pancreatic cancer via regulating apoptosis-related genes |
| - | vitro+vivo, | PC, | MIA PaCa-2 |
| 5686- | BJ, | BRU, | A review of Brucea javanica: metabolites, pharmacology and clinical application |
| - | Review, | Var, | NA |
| 5687- | BJ, | Seed Oil of Brucea javanica Induces Apoptotic Death of Acute Myeloid Leukemia Cells via Both the Death Receptors and the Mitochondrial-Related Pathways |
| - | vitro+vivo, | AML, | U937 |
| 5689- | BJ, | Brucea javanica oil inhibited the proliferation, migration, and invasion of oral squamous carcinoma by regulated the MTFR2 pathway |
| - | vitro+vivo, | Oral, | CAL27 |
| 5690- | BJ, | BRU, | Brusatol: A potential sensitizing agent for cancer therapy from Brucea javanica |
| - | Review, | Var, | NA |
| 5692- | BJ, | Seed oil of Brucea javanica induces apoptosis through the PI3K/Akt signaling pathway in acute lymphocytic leukemia Jurkat cells |
| - | vitro+vivo, | AML, | NA |
| 5483- | BM, | The Role of Bacopa monnieri in Alzheimer’s Disease: Mechanisms and Potential Clinical Use—A Review |
| - | Review, | AD, | NA |
| 5478- | BM, | A systematic review of the safety and efficacy on cognitive function of herbal and nutritional medicines in older adults with and without subjective cognitive impairment |
| - | Review, | AD, | NA |
| 5479- | BM, | Importance of high-quality evidence regarding the use of Bacopa monnieri in dementia |
| - | Review, | AD, | NA |
| 5480- | BM, | Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents |
| - | Human, | Nor, | NA |
| 5481- | BM, | Therapeutic potential of Bacopa monnieri extracts against hepatocellular carcinoma through in-vitro and computational studies |
| - | in-vitro, | HCC, | HepG2 |
| 5482- | BM, | Bacopa monnieri protects SH-SY5Y cells against tert-Butyl hydroperoxide-induced cell death via the ERK and PI3K pathways |
| - | in-vitro, | Nor, | NA |
| 5484- | BM, | The Neurocognitive Effects of Bacopa monnieri and Cognitive Training on Markers of Brain Microstructure in Healthy Older Adults |
| - | in-vivo, | AD, | NA |
| 5485- | BM, | Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: A systematic review and network meta-analysis |
| - | Review, | AD, | NA |
| 5486- | BM, | Bacopaside I, acting as an aquaporin 1 inhibitor, ameliorates rheumatoid arthritis via suppressing aquaporin 1-mediated autophagy |
| - | in-vivo, | Arthritis, | NA |
| 5473- | BM, | Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability |
| - | in-vivo, | AD, | NA | - | in-vivo, | Park, | NA |
| 5477- | BM, | The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis. |
| - | in-vitro, | Var, | NA |
| 5474- | BM, | Pharmacological attributes of Bacopa monnieri extract: Current updates and clinical manifestation |
| 5475- | BM, | The Purified Extract from the Medicinal Plant Bacopa monnieri, Bacopaside II, Inhibits Growth of Colon Cancer Cells In Vitro by Inducing Cell Cycle Arrest and Apoptosis |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | Colon, | SW48 | - | in-vitro, | Colon, | SW-620 | - | in-vitro, | CRC, | HCT116 |
| 5476- | BM, | In Vitro Synergistic Inhibition of HT-29 Proliferation and 2H-11 and HUVEC Tubulogenesis by Bacopaside I and II Is Associated with Ca2+ Flux and Loss of Plasma Membrane Integrity |
| - | vitro+vivo, | CRC, | HT29 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid